UNC Researchers Test CAR T-Cell Therapy for Lupus

A Chapel Hill clinical trial explores using reprogrammed T-cells to treat the chronic autoimmune condition.

Updated on Oct. 15, 2026 in Arthritis

UNC Researchers Test CAR T-Cell Therapy for Lupus

Live Poll

Should medical research prioritize experimental treatments for chronic diseases with few existing options?

In 2025, patient Rachel Dib received a CAR T-cell therapy infusion at the University of North Carolina School of Medicine. The experimental procedure allowed her to manage daily tasks more than a year after treatment.

Why it matters

The clinical trial offers a potential new treatment pathway for lupus, a chronic illness that currently has no cure and limited existing therapeutic options. Researchers are testing this cell-based approach to address the autoimmune nature of the disease.

Lupus affects an estimated 1.5 million Americans, with nine of every 10 patients being women aged 15 to 44. The clinical trial investigates the efficacy of CAR T-cell therapy, which involves genetically reprogramming T-cells.

The players

Rachel Dib

She is a patient who participated in a clinical trial for CAR T-cell therapy.

University of North Carolina School of Medicine

It is a medical research institution located in Chapel Hill that hosts clinical trials for autoimmune therapies.

The details

Doctors at the University of North Carolina School of Medicine extract a patient's T-cells and reprogram them to target autoreactive B cells. Following chemotherapy preconditioning, these modified cells are infused back into the patient to combat the disease.

Rachel Dib received her CAR T-cell therapy infusion in 2025.

The Big Picture

The adoption of CAR T-cell therapy for lupus marks a significant expansion of the technology beyond its initial success in oncology. This trial extends the use of CAR T-cell technology into the field of rheumatology.

Patients dealing with lupus may find this research relevant as it signals a shift toward precision medicine for autoimmune disorders. While the therapy is currently part of a clinical trial, it represents a potential future option for managing the disease.

The takeaway

Lupus remains a complex condition without a definitive cure, making clinical trials critical for developing new management strategies. Individuals should consult with their healthcare providers about ongoing research studies that may align with their specific health needs.